AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

@article{Malmstrm2010AdCD40LIT,
  title={AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.},
  author={P U Malmstr{\"o}m and Angelica Loskog and Camilla A Lindqvist and Sara M Mangsbo and Moa E. Fransson and Alkwin Wanders and Truls G{\aa}rdmark and Thomas H. T{\"o}tterman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 12},
  pages={3279-87}
}
PURPOSE Immunotherapy with Bacillus Calmette-Guerin (BCG) instillation is recommended for high-risk, non-muscle invasive bladder cancer. Bacillus Calmette-Guerin is not effective in advanced tumors, and better alternatives are warranted. Immunostimulating gene therapy with adenoviral vectors expressing CD40 ligand (AdCD40L) has shown efficacy in tumor models. CD40 ligand stimulates systemic immunity and may be effective in local and invasive human disease. EXPERIMENTAL DESIGN Patients with… CONTINUE READING
41 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…